These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34726506)

  • 1. Antiviral monoclonal antibody cocktails as a modern weapon in combating pandemics.
    Liu D; Shameem M
    Ther Deliv; 2022 Feb; 13(2):67-69. PubMed ID: 34726506
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 Updates: Monoclonal Antibodies for COVID-19.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):16. PubMed ID: 35139286
    [No Abstract]   [Full Text] [Related]  

  • 3. An overview of the development of pharmacotherapeutics targeting SARS-CoV-2.
    Lucaj T; Hay I; Samarbakhsh A; Bedi M; Iyer AK; Gavande NS
    Drug Discov Today; 2024 Sep; 29(9):104126. PubMed ID: 39097220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
    Edwards AM; Baric RS; Saphire EO; Ulmer JB
    Science; 2022 Mar; 375(6585):1133-1139. PubMed ID: 35271333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COVID-19 pandemic: a stress test for clinical epidemiology.
    Pivetta E
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):28-29. PubMed ID: 33412791
    [No Abstract]   [Full Text] [Related]  

  • 6. Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes.
    McGarry BE; Sommers BD; Wilcock AD; Grabowski DC; Barnett ML
    JAMA; 2023 Aug; 330(6):561-563. PubMed ID: 37450293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19.
    Parums DV
    Med Sci Monit; 2021 Aug; 27():e934393. PubMed ID: 34393218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19.
    Merone L; Finlay S
    Aust N Z J Public Health; 2020 Dec; 44(6):437-439. PubMed ID: 33044799
    [No Abstract]   [Full Text] [Related]  

  • 9. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs.
    Iketani S; Ho DD
    Cell Chem Biol; 2024 Apr; 31(4):632-657. PubMed ID: 38640902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2.
    Wang SF; Chen KH; Wang SY; Yarmishyn AA; Lai WY; Lin YY; Wang ML; Chou SJ; Yang YP; Chang YL
    J Chin Med Assoc; 2020 Aug; 83(8):712-718. PubMed ID: 32433345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.
    Tabll AA; Shahein YE; Omran MM; Elnakib MM; Ragheb AA; Amer KE
    Hum Antibodies; 2021; 29(3):179-191. PubMed ID: 33998533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination prevention for COVID-19.
    Cohen MS; Corey L
    Science; 2020 May; 368(6491):551. PubMed ID: 32381692
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of vaccines and antivirals for combating viral pandemics.
    Pardi N; Weissman D
    Nat Biomed Eng; 2020 Dec; 4(12):1128-1133. PubMed ID: 33293724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19.
    Lai SK; McSweeney MD; Pickles RJ
    J Control Release; 2021 Jan; 329():87-95. PubMed ID: 33276017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Strategies Against SARS-CoV-2: A Systems Biology Approach.
    Prates ET; Garvin MR; Jones P; Miller JI; Sullivan KA; Cliff A; Gazolla JGFM; Shah MB; Walker AM; Lane M; Rentsch CT; Justice A; Pavicic M; Romero J; Jacobson D
    Methods Mol Biol; 2022; 2452():317-351. PubMed ID: 35554915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Audio Interview: What the U.S. Response to Covid-19 Looks Like Today.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 Nov; 383(19):e123. PubMed ID: 33211936
    [No Abstract]   [Full Text] [Related]  

  • 18. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
    Bai Y; Shen M; Zhang L
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When RING finger family proteins meet SARS-CoV-2.
    Cai C; Tang YD; Zheng C
    J Med Virol; 2022 Jul; 94(7):2977-2985. PubMed ID: 35257387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.